Opus Genetics IRD
NASDAQ IRD
$4.67 +0.07 (+1.52%)
As of: Sep 4, 2026 · 3:59 PM EDT

Opus Genetics (IRD) EV to EBIT (2010 - 2026)

Analysis

Opus Genetics (IRD) EV to EBIT (2010 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn
10 Opus Genetics 446.86 Mn 358.05 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -15.22
Mar 31, 2026 -18.44
Dec 31, 2025 -8.33
Sep 30, 2025 -9.11
Jun 30, 2025 -2.68
Mar 31, 2025 0.87
Dec 31, 2024 -0.19
Sep 30, 2024 0.29
Jun 30, 2024 0.20
Mar 31, 2024 -0.42
Dec 31, 2023 -3.99
Sep 30, 2023 5.22
Jun 30, 2023 -9.47
Mar 31, 2023 -6.45
Dec 31, 2022 0.90
Sep 30, 2022 -6.14
Jun 30, 2022 -4.34
Mar 31, 2022 -6.59
Dec 31, 2021 -4.98
Sep 30, 2021 -15.70